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In Alzheimer’s disease (AD), amyloid plaques are surrounded by reactive astrocytes with an increased
expression of intermediate ﬁlaments including glial ﬁbrillary acidic protein (GFAP). Different GFAP iso-
forms have been identiﬁed that are differentially expressed by speciﬁc subpopulations of astrocytes and
that impose different properties to the intermediate ﬁlament network. We studied transcript levels and
protein expression patterns of all known GFAP isoforms in human hippocampal AD tissue at different
stages of the disease. Ten different transcripts for GFAP isoforms were detected at different abundancies.
Transcript levels of most isoforms increased with AD progression. GFAPd-immunopositive astrocytes
were observed in subgranular zone, hilus, and stratumelacunosumemoleculare. GFAPd-positive cells
also stained for GFAPa. In AD donors, astrocytes near plaques displayed increased staining of both GFAPa
and GFAPd. The reading-frameeshifted isoform, GFAPþ1, staining was conﬁned to a subset of astrocytes
with long processes, and their number increased in the course of AD. In conclusion, the various GFAP
isoforms show differential transcript levels and are upregulated in a concerted manner in AD. The
GFAPþ1 isoform deﬁnes a unique subset of astrocytes, with numbers increasing with AD progression.
These data indicate the need for future exploration of underlying mechanisms concerning the functions
of GFAPd and GFAPþ1 isoforms in astrocytes and their possible role in AD pathology.
 2014 Elsevier Inc. All rights reserved.1. Introduction
Astrocyte processes envelope neuronal synapses and form,
together with the pre- and postsynaptic elements, the tripartite
synapse. There is ample evidence that astrocytes are actively
involved in modulating synaptic transmission (Halassa and
Haydon, 2010; Lee et al., 2012; Seth and Koul, 2008). In response
to damage inﬂicted to the central nervous system, astrocytes can
change into a so-called reactive state. This transition termedocyte Biology and Neuro-
IN-KNAW), Meibergdreef 47,
65500; fax: þ31 20 5666101.
phuis).
ll rights reserved.astrogliosis is characterized by an increase in the expression of their
main intermediate ﬁlament (IF), glial ﬁbrillary acidic protein
(GFAP), by morphological alterations (hypertrophy) and by func-
tional changes (Kato et al., 1998; Pekny and Nilsson, 2005; Simpson
et al., 2008; Verkhratsky et al., 2010; Vincent et al., 2010). Inter-
mediate ﬁlaments are dynamic structures that are involved in a
range of cellular processes during homeostasis and stress; however,
the functional consequences of increased GFAP expression in
reactive astrocytes are not understood (Middeldorp and Hol, 2011;
Sofroniew and Vinters, 2010).
Amyloid plaques are a neuropathological hallmark of Alz-
heimer’s disease (AD), and they are surrounded by reactive astro-
cytes already at an early stage of the disease (Carter et al., 2012;
Kamphuis et al., 2012; Sofroniew and Vinters, 2010). GFAP expres-
sion is highly associated with plaque load and, to a lesser extent,
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Muramori et al., 1998; Vehmas et al., 2003). Recently, it has been
shown that reactive gliosis limits amyloid deposition (Chakrabarty
et al., 2010; Furman et al., 2012), and that the presence of GFAP
plays a crucial role in this (Kraft et al., 2012). Furthermore, GFAP/
vimentin double knockout mice show a reduced hypertrophy of cell
processes and greater sensitivity for spinal cord injury and as well
as having a larger infarct volume after ischemia, indicating that
GFAP has protective role of GFAP and that a proper IF network is a
crucial component of reactive gliosis (Li et al., 2008; Nawashiro
et al., 1998, 2000; Wilhelmsson et al., 2004). Several functional
consequences of a change in GFAP IF network have been reported.
GFAP overexpression, GFAP isoform ratios, and mutations in the tail
and rod domain all inﬂuence IF network structure and reduce the
motility of glioma cells in vitro (Elobeid et al., 2000; Kamphuis et al.,
2012; Lepekhin et al., 2001; Roelofs et al., 2005; Yoshida et al.,
2007). Astrocytes lacking IFs fail to form a barrier-like structure
around amyloid-b (Ab) deposits (Lepekhin et al., 2001; Lu et al.,
2011; Wilhelmsson et al., 2004; Xu et al., 1999). Furthermore, evi-
dence has been presented that the GFAP network is involved in
intracellular vesicle motility (Potokar et al., 2007, 2010), and that
the IF network serves as a platform for signal transduction (Pallari
and Eriksson, 2006) and translation (Kim and Coulombe, 2010).
A variety of GFAP isoforms have been described. To date, at least
9 splice variants of GFAP transcripts have been identiﬁed in
different species (human, mouse, rat) (Kamphuis et al., 2012;
Middeldorp and Hol, 2011). The canonical form, GFAPa, has 9
exons and is speciﬁcally expressed in astrocytes. GFAPb has an
alternative upstream transcriptional start site in the 5’UTR
(Condorelli et al., 1999b; Feinstein et al., 1992; Kamphuis et al.,
2012). GFAPg lacks exon 1 and includes the last 126 bp of intron
1-2 (Zelenika et al., 1995). Four splice variants, GFAPDEx6,
GFAPD164, GFAPD135, and GFAPDEx7, skip sequences in exon 6/7,
and were identiﬁed in AD tissue, focal lesions assocated with
chronic epilepsy, and a speciﬁc human astrocyte subtype (Boer
et al., 2010; Hol et al., 2003; Kamphuis et al., 2012; Middeldorp
et al., 2009b). These splice variants encode for a frameshifted
GFAP protein, termed GFAPþ1, with a frameshifted carboxy-
terminus against which we have raised a speciﬁc antibody named
GFAPþ1 (Hol et al., 2003; Middeldorp et al., 2009b). In an article by
Zelenika et al., a transcript including the last 284 bp of intron 8e9
was reported, which we found to be highly expressed in the mouse
brain and which we termed GFAP-zeta (GFAPz) (Kamphuis et al.,
2012; Zelenika et al., 1995). In GFAPd and GFAPk isoforms, exons 8
and 9 are replaced by intron 7e8 sequences (Blechingberg et al.,
2007; Kamphuis et al., 2012; Nielsen et al., 2002; Roelofs et al.,
2005). GFAPd is highly expressed in proliferating cells in the sub-
ventricular zone and in the subpial layer of the human brain
(Roelofs et al., 2005; van den Berge et al., 2010). The different splice
variants result in different GFAP isoforms with variable C-terminal
regions. Because the tail domains are important for the assembly of
GFAP ﬁlaments and for the binding of interacting proteins (Nielsen
et al., 2002; Perng et al., 2008), a differential expression may result
in a different GFAP cellular IF network, leading to a different
morphology and even an altered function of astrocytes. Recently we
published an extensive survey on the gene expression of GFAP
isoforms and GFAP protein distribution in the mouse brain and in
response to plaque-related gliosis in an AD mouse model
(Kamphuis et al., 2012). The gene expression proﬁle of the GFAP-
isoforms was shown to remain invariable with age and did not
alter as a consequence of plaque-related gliosis. At the protein level,
only GFAPa and GFAPd could be localized, with GFAPd present at
relatively high levels not only in neurogenic cells in the sub-
ventricular and subgranular zones but also in astrocytes located in
the subpial region (Kamphuis et al., 2012).In previous articles, we reported observations on the differ-
ential expression of GFAPd (Roelofs et al., 2005; van den Berge
et al., 2010) and GFAPþ1 (Boer et al., 2010; Hol et al., 2003;
Middeldorp et al., 2009b) in distinct types of astrocytes in the
human brain; however, a systematic description of all human
GFAP isoforms in relation to AD pathology has not yet been
published. To this end, we investigated the changes in GFAP iso-
form transcript levels and protein distribution in AD tissue and at
different stages of the disease. We focused on the hippocampus,
which is one of the brain areas earliest and most severely affected
by AD (Braak and Braak, 1991; Gomez-Isla et al., 1997). We
collected tissue from a large number of donors that were classiﬁed
for amyloid stage (Thal et al., 2000a) and Braak stage of neuro-
ﬁbrillar degeneration (Braak and Braak, 1991), as indicators for the
progression of AD.
2. Methods
2.1. Human post-mortem brain material
Human post-mortem brain material was obtained from the
Netherlands Brain Bank (NBB). Snap-frozen (non-ﬁxed and without
freeze protection) tissue of the hippocampal area was obtained. For
all 75 donors, the medical history was retrieved by the NBB, and an
extensive neuropathological assessment was performed by the NBB
on multiple brain areas. Next to the staging for amyloid load (Thal
et al., 2000a), all donors were also Braak staged for tau (Braak
and Braak, 1991). The hippocampal area included the dentate gy-
rus (DG), area CA1-4, and variable parts of subiculum and, occa-
sionally, entorhinal cortex.
Details of the donors, ranked according to their amyloid score (O,
A, B, C), are presented in Supplementary Table 1. Donors were sex
and age matched as much as possible, but the amyloid O donors of
the frozen tissue were signiﬁcantly younger compared to the am-
yloid B (p< 0.047) and amyloid C (p< 0.023) donors. The age of the
amyloid O group (n ¼ 13) ranged from 51e96 years (mean, 70
years); amyloid A (n ¼ 8) ranged from 64e90 years (mean, 76
years); amyloid B (n ¼ 10) ranged from 64e93 years (mean, 83
years); and amyloid C (n ¼ 34) ranged from 57e96 years (mean, 80
years). In addition, 10 donors were included that did not have an
NBB-documented amyloid score, but were scored for tau pathology.
The post-mortem delay ranged from 3e11 hours (mean 6 hours)
and did not differ between groups. In addition, the pH of the CSF (no
signiﬁcant differences among groups), brain weight (reduced by
15% in amyloid C vs. amyloid O; p< 0.001), and ApoE genotypewere
provided for most donors.
2.2. Cloning GFAP splice variants into pcDNA3
Expression plasmids containing full length isoforms were con-
structed by modifying the pcDNA3-GFAPa full-length plasmid
(Roelofs et al., 2005). (For details, see Supplementary Material and
Methods.)
2.3. RNA isolation and real-time quantitative polymerase reaction
assays
Cryosections of 10-mm thickness were cut, and 20 sections were
collected in a tube kept cold at 20 C. Tissue sections were sub-
sequently thawed and dissolved by adding 1 mL of TRIzol (Life
Technologies) at room temperature, followed by thorough vortex-
ing. RNA was isolated from the 400 mL aqueous phase by precipi-
tation at 20 C overnight in 400 mL isopropanol, with the addition
of 1 mL of 20 mg/mL glycogen (Roche). The quality of the RNA was
determined on a Bioanalyzer (Agilent Technologies) and expressed
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and used as a template to generate cDNA following the manufac-
turer’s instructions (Quantitect; Qiagen) using a combination of
oligo-dT and random primers for optimal priming. Incubation was
for 30 minutes at 42 C. Diluted cDNA served as a template in real-
time quantitative polymerase chain reaction (PCR) assays (SYBR
Green PCR Master Mix; Applied Biosystems). (For primer se-
quences, see Supplementary Table 2; genes are indicated with the
abbreviated formal National Center for Biotechnology Information
[NCBI] name.)
Expression levels of 13 candidate reference genes (GAPDH,
ACTB, PPIA, UBE2D2, EEF1A, RPS27A, AARS, XPNPEP1, RPLP0, IPO,
POLR2A, HPRT, RNA18S5) were determined (Durrenberger et al.,
2012; Wang et al., 2012) in a larger set of donors. A geNorm anal-
ysis on the stability of the transcript levels led us to exclude
POLR2A, HPRT, and RNA18S5 from the set of reference genes
(Vandesompele et al., 2002).
Primer speciﬁcity and sensitivity was tested on dilution series of
cloned GFAP isoforms in pcDNA3 ranging from 1 nge4 fg input.
Particular attention was given to potential unwanted cross-
ampliﬁcation of GFAPa, the most abundant transcript isoform
present in brain tissue. In addition, qPCR products were also run on
agarose gels to conﬁrm the anticipated amplicon size (data not
shown).
2.4. Immunocytochemistry
Sections (10 mm) cut from frozen brain samples were mounted
on Superfrost Plus slides (Thermo Scientiﬁc), ﬁxed for 10 minutes
with freshly prepared 4% paraformaldehyde in phosphate-
buffered saline (PBS; 137 mmol/L NaCl, 2.7 mmol/L KCl, 1.8
mmol/L KH2PO4, and 4 mmol/L Na2HPO4, pH 7.4), washed, and
blocked with 10% normal donkey serum þ 0.04% Triton X-100 in
0.05 mol/L phosphate buffer (PB; pH7.4) for 1 hour. Incubation
with the different GFAP-isoformespeciﬁc antibodies was carried
out overnight at room temperature in 3% normal donkey serum þ
0.04% Triton X-100 in PB. Immunostaining was visualized with
1:1400 diluted Cy3- or AlexaFluor 488econjugated secondary
antibodies (Jackson ImmunoResearch Laboratories) incubated for
2 hours in PB and washed in PB. Sections were treated with Sudan
Black (0.3% Sudan Black in 70% ethanol) for 7 minutes to quench
autoﬂuorescence, and were then washed in 70% ethanol for 50
seconds. After a ﬁnal wash in PB, sections were cover-slipped in
Vectashield with added DAPI as a nuclear dye (Vector Labora-
tories) and viewed with a Leica DMRE ﬂuorescence microscope.
Plaques were localized with thioﬂavin-S or by antibodies against
Ab (6E10-Signet/Covance). Negative controls were included by
omitting the primary antibody, but these did not yield staining
patterns, and autoﬂuorescence was recognized by a positive signal
at all ﬁlter settings.
U343 cells and SW-13cl.2 cells, cultured on gelatin-coated cov-
erslips, were rinsed with PBS, and after ﬁxation with 4% formalin in
PBS, immunostainings were carried out along the procedure
described above for cryosections.
For double-labeling of 2 rabbit primary antibodies (GFAPþ1 in
combination with GFAPpan or S100B), the protocol was adapted,
such that ﬁrst primary antibody was applied as before, followed by
incubation with Fabeanti-rabbit Cy3 antibody (Jackson Immuno
Research,1:800 inTris-buffered salineebovine serum albumin [TBS-
BSA]). After rinsing, sectionswere incubated for at least 5 hourswith
unlabeled Fabeanti-rabbit fragments (Jackson Immuno Research,
1:150 in TBS-BSA), followed by incubation with the second primary
antibody and Fabeanti-rabbit AlexaFluor 488 as before. As a control,
1 of the primary antibodies was omitted to conﬁrm speciﬁcity of the
detected patterns.2.5. Quantiﬁcation of GFAPþ1 cells and amyloid plaques
For quantiﬁcation of the number of GFAPþ1 cells and amyloid
plaque load, frozen tissue sections were double stained. All sections
were stained for GFAPþ1 (visualized with Cy3) and Ab (6E10, visu-
alized with AlexaFluor 488) following the described immunoﬂuo-
rescence protocol. Images of sections were captured at 5
magniﬁcation with a Zeiss Axioplan 2 microscope (Zeiss, Germany)
equipped with an Evolution QEi camera (Sony) in a tiled fashion.
The tiles were combined with Image-Pro software (Media Cyber-
netics) to form an image of the entire section. Next, the number of
GFAPþ1 cells in the images was counted manually. Cells qualiﬁed as
GFAPþ1 positive when a cell body was observed from which pro-
cesses extended, or when the GFAPþ1-immunoreactive processes
all directed toward a central point that corresponds with the likely
position of the cell body deeper in the tissue. GFAPþ1-expressing
ﬁbers without a clear indication of the associated cell bodywere left
out of the quantiﬁcation.
For the quantiﬁcation of amyloid plaques in the hippocampal
area, a macro for automated segregation was developed for Image-
Pro software (MediaCybernetics, Bethesda, MD). In the combined
tiled image of thewhole tissue section, amaskwould be placed over
all green ﬂuorescent structures with intensity greater than 3 times
the background intensity. The mask was inspected manually to
correct for obvious staining artifacts, and the total area of Ab
immunoreactivity was automatically calculated. Subsequently, an
outline of the whole sectionwas made to calculate the surface area,
to correct for differences in section size between donors. The per-
centage of the total surface area covered by Ab immunoreactivity
was calculated.
To determine whether the quantiﬁcation of the number of
GFAPþ1 positive cells in a single section accurately reﬂects the total
number of GFAPþ1 positive cells, we analyzed the intra-donor
variation. The number of GFAPþ1 positive cells was determined in
7 sections of a single hippocampus, spanning a total distance of 270
mm. The number of GFAPþ1 positive cells ranged from aminimumof
20 to a maximum of 28, with an average of 25 cells and a variance of
12%. Compared to the much larger variation between donors in the
different Braak groups using a single section for each donor
(average variance over the different Braak groups was 48%), we
concluded that measuring 1 section per donor was sufﬁcient.
2.6. Western blot
To obtain recombinant protein samples for western blotting,
pcDNA3 expression plasmids for GFAPa, GFAPd, GFAPk, GFAPD135,
GFAPD164, and GFAPDEx6 were transfected separately into SW-
13cl.2 cells. Protein was isolated from these cells by homogeniza-
tion with lysis buffer (0.1 mol/L NaCl, 0.01 mol/L Tris-HCl [pH 7.6],
and 1 mmol ethylenediaminetetraacetic acid (EDTA; pH 8.0)) sup-
plemented with a protease inhibitor cocktail (Roche). The samples
were dissolved in 2x loading buffer (2x: 100mmol/L Tris, 4% sodium
dodecyl sulfate [SDS], 20% glycerol, 200 mmol/L ditthiothreitol
(DTT), and 0.006% bromophenol blue) and boiled for 5 minutes.
Subsequently, the samples were run on a 7.5% SDSepolyacrylamide
gel electrophoresis (SDS-PAGE) gel and blotted semi-dry on nitro-
cellulose. Primary antibodies GFAPþ1, GFAPpan, and GFAPc-term
(see Table S3 for details) were diluted in Supermix (0.05 mol/L Tris,
0.9%NaCl, 0.25% gelatin, and0.5% TritonX-100, pH7.4). The next day,
the blotswerewashedwith TBS-T (100mmol/LTris-HCl [pH7.4],150
mmol/L NaCl, with 0.2% Tween-20) and incubated with anti-rabbit
IRDye800 or anti-goat IRDye800 (1:5000; Rockland Immunochem-
icals, Gilbertsville, PA) in Supermix for 1 hour at room temperature.
After 3 washes in TBS, bands were visualized with the Odyssey
Infrared Imaging System (LI-COR Biosciences, Lincoln, NB).
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Antibodies used in this study are listed in Supplementary
Table 3. Based on the differential sequences in the C-terminal do-
mains of the GFAP isoforms, isoform-speciﬁc epitopes were
selected. The speciﬁcity of the antibodies against human GFAPd and
GFAPþ1 has been described previously (Middeldorp et al., 2009b;
Roelofs et al., 2005). Two different polyclonal antibodies against
the speciﬁc sequences in human GFAPkwere raised in rabbits. Basic
Local Alignment Search Tool (BLAST; NCBI) analysis did not show
signiﬁcant homologies of the peptide sequences with other pro-
teins. The peptide was either coupled to thyroglobulin or to keyhole
limpet hemocyanin (KLH) in a 1:1 ratio using glutaraldehyde, dia-
lyzed against 2% sodium metabisulphite (pH 6.5). After collecting
pre-immune serum, rabbits were injected with 2e5 mg of coupled
peptide mixed with either Specol or Freund’s Complete Adjuvant,
followed by 2 or 3 booster immunizations. Both antibodies gave
similar results.
2.8. Cell culture and transfections
The human adrenal carcinoma cell line SW-13cl.2 (Sarria
et al., 1994) and astrocytoma cell line U343 were used for
transfection and stainings. SW-13cl.2 cells do not express inter-
mediate ﬁlaments and U343 cells express vimentin, nestin, and
GFAP, but under normal circumstances no GFAPþ1 isoforms
(Middeldorp et al., 2009b). (For details, please see Supplemental
data.)
2.9. Ab preparation and MTT assay
Ab1-42 preparations enriched in oligomers and ﬁbrils were
obtained as described previously (Chafekar et al., 2007). In short,
Ab1-42 peptide (Anaspec, San Jose, CA) was dissolved in
1,1,1,3,3,3-hexaﬂuoroisopropanol (1 mg/mL; Sigma, St. Louis, MO),
resuspended in dimethyl sulfoxide (DMSO) to a concentration of
2.5 mmol/L, and bath sonicated for 10 minutes. Oligomer
enrichment was realized by addition of phenol redefree DMEM
under continuous vortexing and incubation at 4 C for 24 hours.
For ﬁbril enrichment, 10 mmol/L HCl was added under contin-
uous vortexing, followed by incubation at 37 C for 24 hours.
Protein concentrations were measured with a Bradford protein
assay (Biorad, Hercules, CA), and characterization of the Ab1-42
aggregates was performed by electron microscopy and a thio-
ﬂavin T assay.
Metabolic activity of cells was assessed by the 3-(4,5-
dimthylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay as described previously (Middeldorp et al., 2009a). Brieﬂy,
U343 cells were incubated with 1 mmol/L oligomeric or ﬁbrillar
Ab1-42 for 1 day, 3 days, or 7 days. After that, cells were incubated
with MTT (0.25 mg/mL) for 4 hours at 37 C. Next, the formazan
crystals generated by the cells as a result of MTT conversion by
mitochondrial activity were dissolved in DMSO, and absorbance
wasmeasured at 570 nm on amicroplate reader (Molecular Devices
Corp., Sunnyvale, CA).
2.10. Statistical analyses
Data from human hippocampal tissue were non-normally
distributed and did not show equality of variances between
groups; therefore analyses were performed using non-parametric
methods. To describe the central tendency and the spread, data
are presented as median and the 25the75th percentile range. The
relationship between individual groups (Braak stage, age, and sex)
was determined using a KruskaleWallis one-way analysis ofvariance. Correlation analyses were performed by calculating
Spearman rank correlation coefﬁcient (Rs). All tests were consid-
ered statistically signiﬁcant at p < 0.05.
3. Results
3.1. Development of isoform speciﬁc qPCR assays
Primer design for GFAP-speciﬁc isoform qPCR assays was based
on targeting unique sequences in the different GFAP isoforms
following the same approach as described for the mouse GFAP
isoforms (Kamphuis et al., 2012). Assay speciﬁcity and sensitivity
was tested on serial dilutions of plasmid templates of the different
GFAP isoforms. No cross-reactionwas found for the speciﬁc primers
for GFAPb, GFAPg, GFAPd, GFAPk, GFAPD135, GFAPD164, GFAPDEx6,
and GFAPDEx7. GFAPz-speciﬁc primers were positioned in intron 8/
9 and exon 9 (Zelenika et al., 1995). On human cDNA, this resulted in
clear ampliﬁcation in all samples, whereas no ampliﬁcation was
found when omitting the reverse transcription step.
3.2. GFAP isoform transcript level proﬁle in human hippocampus
For the analysis of the qPCR data, a normalization factor based
on 10 selected reference genes was used. RNA samples with a RIN
value of less than 5.0 were excluded from analysis because they had
a poor correlation with the normalization factor. Of the remaining
samples included in the study here, the correlation between the RIN
value and the normalization factor was RS¼ 0.83; n¼ 75; p< 0.001
[Spearman rank correlation coefﬁcient] (Fig. 1A), indicating that
differences in RNA quality signiﬁcantly contribute to the variation
of assessed transcript levels, and that a proper normalization pro-
cedure is require to correct for this (Fleige and Pfafﬂ, 2006). In
addition, the efﬁciency of the qPCR assays was not affected when
using cDNA samples from RNA with RIN values within the range of
5.0e8.0 (data not shown).
GFAPa, GFAPb, GFAPg, GFAPd, GFAPk, GFAPz, GFAPDEx7, and
GFAPD135 transcript levels were determined in all 75 samples.
GFAPDEx6 was detected in 56 of the 75 samples, and GFAPD164 in
49 of 75 samples without clear correlation with AD stage.
Using plasmid calibration curves, the relative expression of the
isoforms was estimated. Setting the amount of GFAPa at 100%; tran-
script levels of the other isoforms were calculated as a percentage of
GFAPaexpression todetermine aproﬁle foreach individual sample. In
the amyloidOgroup,medianvalues for the different isoformswere as
follows: GFAPb, 0.00120% (0.0008e0.0016); GFAPd, 1.5% (1.3e1.7);
GFAPk 1.1% (0.7e1.7); GFAPz, 0.21% (0.17e0.38); GFAPD135, 0.24%
(0.21e0.28); GFAPD164, 0.00017% (0.00006e0.00036; n ¼ 8), GFAP-
DEx6, 0.009% (0.001e0.012; n ¼ 9), and GFAPDEx7, 0.006%
(0.005e0.014) (n ¼ 13; median and 25the75th percentile range).
Statistical analysis of the proﬁles revealed a signiﬁcantly reduced
contribution ofGFAPb at Braak stages 2, 3, 4, and 5 (for each stage, p<
0.003), reaching an 8-fold reduction compared to Braak stage
0 (0.00015% vs. 0.00120%) at Braak stage 3.
None of the other isoforms showed a signiﬁcant change in the
relative expression proﬁle related to either amyloid stage (O, A, B,
or C), Braak stage, or age (51e96 years).
3.3. GFAP isoform transcript levels are increased in human AD
With respect to amyloid score (Table 1), statistically signiﬁcantly
altered GFAP transcript levels were found for GFAPa, GFAPd, GFAPz,
GFAPk, GFAPD135, and GFAPDEx7 (KruskaleWallis One-way anal-
ysis of variance on ranks; p < 0.05). Compared to amyloid O, GFAPa
levels signiﬁcantly increased 1.3-fold in amyloid A, 2.1-fold in amy-
loid B, and 2.5-fold in amyloid C samples (Fig. 1B). A comparable
Fig. 1. Transcript levels. (A) The normalization factor, calculated as the geomean of
highly linked transcript levels of 10 different reference genes, shows a signiﬁcant
correlation with the quality of the isolated RNA expressed as RNA integrity number
(RIN) with RS ¼ 0.83. (B) GFAPa transcript levels are signiﬁcantly increased in all
amyloid stages and (C) Braak stages. Boundaries of the box indicate the 25th and 75th
percentiles, and the line within the box marks the median. Whiskers indicate the 10th
and 90th percentiles; single points are outliers. Abbreviation: AU, arbitrary units.
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found for the other isoforms, although the changes in amyloid A
were not statistically signiﬁcant (Table 1). Transcript levels of genes
encoding for other intermediate ﬁlament genes vimentin, nestin,
synemin-a, and synemin-b were also increased along the same
pattern as that of GFAP (Table 1). In contrast, other astrocyte speciﬁcgenes were decreased (glutamate transporter 1; SLC1A2 or GLT1) or
not signiﬁcantly changed (glutamine synthetase; GLUL) (Table 1).
With respect to the Braak stages (Table 2), the transcript levels
for GFAPa increased in 2 phases: approximately a 2-fold elevation at
Braak 1, Braak 2, and Braak 3, and a further increase to approxi-
mately 3-fold at Braak 4, Braak 5, and Braak 6 (Fig. 1C). GFAPd,
GFAPz, GFAPk, and GFAPD135 followed the same pattern. GFAPb
signiﬁcantly decreased in Braak stages 3 and 4, and recovered
thereafter (Table 2). The decreased expression levels of GFAPb, with
the increase in the other isoforms at the same time, relates to the
reduced contribution of GFAPb in the proﬁle at Braak stages 2, 3, 4,
and 5, as described above. GFAPDEx7 levels initially had a similar
but non-signiﬁcant trend for a decrease in early Braak stages, but
increased at later Braak stages (Table 2).
3.4. GFAP isoform speciﬁc antibodies
To test the isoform speciﬁcity of the different antibodies, a
Western blot loadedwith the 6 different recombinant GFAP isoform
proteins, obtained by plasmid transfection in SW-13cl.2 cells, was
stained. The GFAPpan antibody, frequently used as a marker for
astrocytes, recognized all GFAP isoforms (Fig. 2A). The GFAPc-term
antibody against the C-terminus of GFAPa did not stain GFAPDEx6
and GFAPD164 protein or GFAPd and GFAPk, only GFAPa and the in-
frame isoformGFAPD135 (Fig. 2B). Staining of theWestern blot with
the GFAPþ1 antibody resulted in 1 band of approximately 50 kDa in
the lanes containing GFAPD164 and GFAPDEx6 protein (Fig. 2C). The
GFAPD164 band was slightly higher than the GFAPDEx6 band,
reﬂecting the 19 amino acids difference between the 2 isoforms. No
bands were detected with the GFAPþ1 antibody in protein samples
of GFAPa, GFAPd, GFAPk, and GFAPD135. These data are in agree-
ment with our earlier ﬁndings (Middeldorp et al., 2009b). The
GFAPk antibody recognized only GFAPk (Fig. 2D). The speciﬁcity of
the GFAPd antibody was demonstrated previously (Roelofs et al.,
2005). For immunostainings, a GFAPmono antibody was used that
recognizes GFAPa, -d, -k, and D135, but not any of the GFAPþ1 iso-
forms (Kamphuis et al., 2012).
3.5. GFAP isoform immunostaining
Immunoﬂuorescent stainings on brieﬂy ﬁxed cryosections re-
sults in a much improved detection of intermediate ﬁlament
staining compared to parafﬁn-embedded sections, as we have used
in earlier studies (Roelofs et al., 2005; van den Berge et al., 2010). In
cryosections, a dense network of processes immunopositive for
GFAPpan, GFAPmono, or GFAPc-termwas observed throughout the
hippocampus of controls and AD donors at all stages. The staining
intensity of this network in the subiculum was much lower. Un-
expectedly, GFAPpan, GFAPmono, or GFAPc-term staining intensity
was not strikingly increased in astrocytes around plaques in the
hilus and CA4 region of the hippocampus (Fig. 3A). In contrast,
plaque-associated astrocytes in CA1-3 and the subiculum showed a
profound increase of GFAP staining intensity compared to non-
plaque areas (Fig. 3B). In these areas and in the molecular layer of
the dentate gyrus, we also detected many examples of plaques
without any sign of gliosis (Figs. 3B, 4B). In addition, reactive as-
trocytes were found that surrounded small areas of Ab staining
with a non-ﬁlamentous pattern (Fig. 3C).
GFAPd-stained astrocytes were found throughout the hippo-
campus, but in some areas GFAPd immunoreactivity was consis-
tently more prominent. In particular, all astrocytes in the dentate
gyrus subgranular zone, hilus, and CA4 area displayed intense
GFAPd staining (Fig. 3D and E). Subgranular zone astrocytes
extended long, GFAPd-positive processes into the granular layer and
the molecular layer (Fig. 3E). Few GFAPd-positive astrocytes were
Table 1
Results of quantitative polymerase chain reaciton assays
Isoforma Amyloid O (n ¼ 13) Amyloid A (n ¼ 8) Amyloid B (n ¼ 10) Amyloid C (n ¼ 34)
GFAPa 1.00 (0.82e1.67) 1.48 (1.12e1.74) 1.88* (1.40e2.74) 2.58*** (1.70e3.85)
GFAPb 1.00 (0.88e1.11) 1.24 (1.01e2.48) 0.98 (0.35e2.00) 1.83 (0.79e3.16)
GFAPd 1.00 (0.47e1.26) 1.18 (0.62e1.41) 1.16 (0.89e1.93) 1.94*** (1.44e2.75)
GFAPz 1.00 (0.57e1.27) 0.90 (0.57e1.30) 2.38** (1.35e2.69) 2.93** (1.35e3.77)
GFAPk 1.00 (0.86e1.58) 0.92 (0.75e1.56) 1.78* (1.46e2.96) 2.30** (1.62e4.01)
GFAPD135 1.00 (0.45e1.21) 1.01 (0.74e1.34) 1.34* (0.99e1.76) 1.87*** (1.28e2.30)
GFAPD164b 1.00 (0.06e1.50) 0.74 (0.43e1.74) 1.68 (0.59e2.90) 0.94 (0.06e3.57)
GFAPDEx6b 1.00 (0.03e1.78) 1.17 (0.91e1.36) 1.54 (0.91e3.93) 1.29 (0.23e2.38)
GFAPDEx7 1.00 (0.50e1.78) 1.39 (0.99e1.87) 0.99 (0.52e1.84) 2.26 (1.15e3.28)
Vimentin 1.00 (0.82e1.68) 1.39 (1.27e1.66) 1.98** (1.34e2.57) 1.95*** (1.59e2.57)
Nestin 1.00 (0.81e1.84) 1.06 (0.91e1.49) 1.93** (1.74e2.22) 2.00** (1.65e2.56)
Synemin-a 1.00 (0.93e1.27) 1.15 (0.96e1.24) 1.60* (1.16e1.94) 1.89*** (1.54e2.25)
Synemineb 1.00 (0.49e1.29) 0.94 (0.84e1.17) 1.76** (1.26e2.25) 1.86*** (1.44e2.70)
SLCLA2 1.00 (0.79e1.09) 1.11 (0.87e1.24) 1.02 (0.83e1.15) 0.70* (0.44e0.87)
GLUL 1.00 (0.82e1.04) 0.86 (0.62e1.10) 0.97 (0.70e1.36) 0.82 (0.64e1.08)
Data are presented as median fold change compared to expression levels quantiﬁed in amyloid O. Data in parentheses are 25the75th percentiles.
* p < 0.05; ** p < 0.01; *** p < 0.002.
a Note that the different isoforms have very different transcript levels. Setting GFAPa at 100%, the median expression level of the other isoforms in the amyloid O group was
as follows: GFAPb, 0.0012%; GFAPd, 1.5%; GFAPk, 1.1%; GFAPz, 0.21%; GFAPD135, 0.24%; GFAPD164, 0.00017%; GFAPDEx6, 0.009%; and GFAPDEx7, 0.006%.
b GFAPD164 and GFAPDEx6 are not detectable in all samples: GFAPD164 in 32/65 and GFAPDEx6 45/65 without preference for any of the amyloid stages. Data presented are
based on samples with detectable levels.
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were found in the stratum lacunosum-moleculare of CA1-3 and the
alveus. In the pyramidal cell layer of CA1-3 subregions and the
subiculum, GFAPd staining was observed in only a few astrocytes.
Double staining showed co-localization of GFAPd-positive astro-
cytes with GFAPc-term (Fig. 3E and F). In general, the GFAPd was
preferentially localized in the more proximal processes of cells,
resulting in a typical star-shaped pattern, whereas GFAPc-term
reached into the ﬁner branches of the processes, resulting in a
more mesh-like appearance of the staining (Fig. 3E and F). No
alteration of this GFAPd distribution patternwas noted at any of the
AD stages. Plaque-associated astrocytes in the subgranular zone,
hilus, and CA4 region did not show a profound increase GFAPd or
GFAPc-term staining intensity (Fig. 4A). In contrast, astrocytes near
plaques in the CA1-3 or subiculum, had clearly increased expres-
sion of both GFAPc-term and GFAPd, demonstrating the classical
pattern of plaque-associated gliosis (Fig. 4B). GFAPk staining could
not be detected (data not shown).
Vimentin was widely distributed over the whole hippocampus,
with a distribution overlapping that of GFAPc-term and GFAPd.
Intense vimentin staining was found in reactive astrocytesTable 2
Results of quantitative polymerase chain reaction assays
Braak 0 (n ¼ 10) Braak 1 (n ¼ 12) Braak 2 (n ¼ 9) Braak 3 (n ¼
GFAPa 1.00 (0.89e1.12) 1.61* (1.07e1.91) 1.84** (1.50e2.29) 2.28*** (1.70
GFAPb 1.00 (0.78e1.65) 0.83 (0.73e2.28) 0.39* (0.25e0.85) 0.33*** (0.26
GFAPd 1.00 (0.58e1.30) 1.23 (0.70e1.34) 1.08 (0.80e1.58) 1.72 (0.93
GFAPz 1.00 (0.55e1.75) 0.95 (0.64e2.20) 0.88 (0.78e1.03) 1.03 (0.89
GFAPk 1.00 (0.72e1.52) 1.38 (0.83e2.04) 1.53 (0.97e1.72) 1.36 (0.98
GFAPD135 1.00 (0.77e1.65) 1.58 (0.92e1.93) 2.03 (1.59e2.29) 2.26 (1.89
GFAPD164a 1.00 (0.06e2.41) 1.23 (0.55e2.08) 0.29 (0.02e2.09) 0.67 (0.04
GFAPDEx6a 1.00 (0.05e1.77) 0.70 (0.07e1.54) 0.70 (0.50e1.69) 0.05 (0.02
GFAPDEx7 1.00 (0.64e1.89) 0.89 (0.59e1.11) 0.48 (0.32e1.13) 1.08 (0.53
Vimentin 1.00 (0.83e1.20) 1.47** (1.35e1.75) 1.89** (1.45e2.12) 1.88*** (1.71
Nestin 1.00 (0.87e1.51) 1.60 (1.17e1.84) 1.92* (1.33e2.10) 1.51 (1.20
Synemin-a 1.00 (0.85e1.29) 1.06 (0.88e1.16) 1.08 (0.97e1.48) 1.36 (0.96
Synemin-b 1.00 (0.55e1.31) 1.16 (0.95e1.50) 1.60* (1.09e1.62) 1.48* (1.30
SLCLA2 1.00 (0.87e1.36) 1.04 (0.85e1.18) 0.96 (0.63e1.32) 1.20 (0.94
GLUL 1.00 (0.85e1.07) 0.96 (0.72e1.16 0.97 (0.76e1.21) 0.99 (0.84
Data are presented as median fold change compared to transcript levels quantiﬁed in Br
Key: Rs, Spearman rank correlation coefﬁcient against Braak stage.
* p < 0.05; ** p < 0.01; *** p < 0.002.
a GFAPD164 and GFAPDEx6 are not detectable in all samples: GFAPD164 in 49/75 and(Fig. 4C and D). Many examples of dense cored plaques were found
with 1 or more strongly vimentin-positive, GFAPd-negative cells in
or near the plaque with few short processes (Fig. 4D), tentatively
being activated microglia (Jiang et al., 2012).
Nestin expressionwas generally not detected in astrocytes in the
brain parenchyma. Few cells in subgranular zone were immuno-
positive and formed a network of ﬁne processes. This staining
pattern was observed in Braak 0e2 donors only (Fig. 4E). The
nestin-positive cells in subgranular zone were heterogeneous in
their staining intensity for GFAPd (Fig. 4E) and vimentin (not
shown). Reactive astrocytes in the hilus-CA4 region were mostly
nestin positive (Fig. 4C), whereas GFAPd-positive reactive astrocytes
near plaques in the CA1-3 and subiculum were not (Fig. 4D).
It has been documented that synemin is expressed by reactive
astrocytes (Jing et al., 2007), but its expression in AD-related gliosis
has not been described. A few strongly stained cells were observed
in the hippocampus, but in most cases without clear spatial relation
to plaques or reactive gliosis (Fig. 4F).
GFAPþ1 staining was detected in a subpopulation of cells with
a very characteristic morphology, as reported previously (Boer
et al., 2010; Hol et al., 2003; Middeldorp et al., 2009b).9) Braak 4 (n ¼ 8) Braak 5 (n ¼ 15) Braak 6 (n ¼ 12) Rs
e3.01) 2.51*** (2.12e4.11) 2.97*** (2.25e4.36) 2.90*** (2.66e4.14) 0.59***
e0.69) 1.41 (0.88e1.80) 1.23 (0.74e1.95) 2.48* (1.50e4.18) 0.20
e1.96) 2.26 (0.71e3.18) 2.04*** (1.64e2.74) 2.20** (1.50e2.95) 0.52***
e1.80) 1.35 (0.70e1.98) 2.63** (1.75e3.49) 2.87* (2.42e3.30) 0.48***
e1.73) 1.93* (1.24e3.13) 2.41** (1.72e3.06) 2.58** (1.64e3.37) 0.49***
e2.74) 3.23** (2.19e3.57) 3.18*** (2.32e4.57) 3.34** (2.31e3.99) 0.59***
e1.48) 2.00 (1.41e2.27) 1.28 (0.10e4.72) 0.69 (0.08e5.15) 0.10
e0.39) 1.63 (1.20e1.90) 1.45 (0.55e2.84) 4.21 (0.31e4.77) 0.17
e1.75) 0.70 (0.59e1.08) 1.17 (0.81e2.40) 2.08 (1.91e2.61) 0.32**
e2.01) 1.95*** (1.84e2.72) 1.92*** (1.50e2.47) 2.59*** (1.95e2.78) 0.53***
e2.21) 2.06** (1.81e2.84) 2.14*** (1.70e2.62) 2.18*** (1.96e2.78) 0.51***
e1.51) 1.24 (1.14e1.63) 1.73* (1.60e2.05) 1.95*** (1.57e2.63) 0.52***
e2.03) 1.50 * (1.43e2.42) 2.03*** (1.77e3.22) 2.09*** (1.64e3.04) 0.55***
e1.40) 0.88 (0.73e1.28) 0.76 (0.49e1.07) 0.69** (0.46e0.89) e0.38***
e1.32) 1.13 (0.90e1.49) 0.93 (0.77e1.34) 0.67 (0.57e0.91) e0.11
aak 0. Data in parentheses are 25the75th percentiles.
GFAPDEx6 in 56/75 without preference for any of the Braak stages.
Fig. 2. Western blot analysis shows GFAP antibody speciﬁcity (A) GFAPpan antibody
detected recombinant protein of all human GFAP isoforms, GFAPa, GFAPd, GFAPk,
GFAPD135, GFAPDEx6, and GFAPD164. (B) GFAPc-term antibody speciﬁcally recognized
GFAPa and GFAPD135 recombinant protein. (C) GFAPþ1 antibody speciﬁcally detected
GFAPD164 and GFAPDEx6 recombinant protein and none of the other human GFAP
isoforms. (D) GFAPk antiserum speciﬁcally recognized the GFAPk isoform. Position of
molecular weight markers is indicated. Expected sizes of the recombinant proteins are:
GFAPa (422 aa) 49.8 kDa; GFAPd (431 aa) 49.5 kDa; GFAPk (438 aa) 50.3 kDa; GFAPD135
(387 aa) 44.5 kDa; GFAPDEx6 (347 aa) 39.8 kDa; and GFAPD164 (366 aa) 42.1 kDa.
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throughout the section in both gray and white matter areas of
controls without dementia as well as in AD patients, following a
similar distribution pattern in all donors, although the number of
GFAPþ1-expressing cells increased with AD progression, as
described in section 3.7. There was no evident association with
plaques, and the morphology of GFAPþ1 cells in areas of astro-
gliosis was not noticeably different from GFAPþ1 cells in non-
gliotic areas. Most frequently, GFAPþ1 cells were found in the
vicinity of the DG (Fig. 5A), in the subventricular zone (SVZ) of
the lateral ventricle (LV) adjoining the hippocampus (Fig. 5B), and
in the subpial layer of the subiculum and entorhinal cortex when
these were included. GFAPþ1-expressing cells in the subpial layer
often extended long processes into deeper layers (Fig. 5C). Some
GFAPþ1 cells detected in our 10-mm hippocampal sections con-
tained many shorter processes and a number of thin longer
processes (Fig. 5D), whereas other GFAPþ1 cells had several long
processes (Fig. 5E). In some cases, we could measure processes
0.75 mm in length without clearly detecting the termination
point of these processes. Cells with these morphologies were
sporadically found at different locations throughout the hippo-
campal area. We also observed rare GFAPþ1 cells with striking
swellings in their processes, which were not clearly terminating
structures, as the processes continued on both sides of the
structures (Fig. 5F; arrows). GFAPþ1 often terminated on blood
vessels, sometimes with clear endfeet (Fig. 5G).3.6. GFAPþ1 astrocytes are mature non-reactive astrocytes
To investigate the identity of the subpopulation of GFAP-
expressing cells, various markers were double-labeled with
GFAPþ1. The soma of most GFAPþ1 cells was negative for GFAPc-
term (Fig. 6A). The processes of GFAPþ1 cells displayed intense
staining intensity, whereas co-staining with GFAPc-term or GFAP-
mono was mostly undetectable (Fig. 6A and B). Occasionally, a
GFAPþ1-positive cell was found that did show detectable GFAPc-
term staining in the soma and the proximal processes (Fig. 6C).
To study whether GFAPþ1 cells are astrocytes or a distinctive
GFAP expressing cell type, we double-labeled for GFAPþ1 and
astrocyte-speciﬁc markers S100B (Fig. 7A) and glutamine synthe-
tase (GS) (Fig. 7BeD) in brain sections of subjects with different
stages of AD. Most, but not all, GFAPþ1 cells co-expressed S100B in
the soma and in some processes proximal to the soma (Fig. 7A,
arrow), except in more distal processes. Many S100B-expressing
astrocytes were negative for GFAPþ1 (Fig. 7A, arrowheads) indi-
cating that GFAPþ1 is expressed only in a small fraction of all S100B-
expressing astrocytes, similar to pan-GFAP and GFAPc-term. The
results for GS were comparable to those for S100B, as most GFAPþ1-
expressing cells also expressed GS in the soma and proximal pro-
cesses but not in the more distal parts of the processes (Fig. 7B,
arrow). Many cells were found to be GS positive but GFAPþ1
negative (Fig. 7B, arrowheads). In some instances, GFAPþ1-labeled
cells were detected that did not express GS (Fig. 7C, arrow) or S100B
(not shown), whereas theywere surrounded by numerous cells that
expressed these proteins (Fig. 7C, arrowheads). GFAPþ1 cells
residing in the subventricular zone did not express GS (Fig. 7D,
arrow), whereas astrocytes in the neighboring parenchyma did
express GS (Fig. 7D, arrowheads). No differences were noted in this
pattern at the different stages of AD.
To determine whether GFAPþ1 cells are reactive astrocytes,
double-labeling of GFAPþ1 with intermediate ﬁlament proteins
vimentin, nestin, and synemin was analyzed. Vimentin, which also
labels endothelial cells of blood vessels (Figs. 4C, 5E, 8A), is co-
expressed in the soma and some proximal processes of GFAPþ1
positive cells (Fig. 8A). Nestin expressionwas generally not found in
astrocytes within the brain parenchyma, only in subventricular
zone astrocytes and in ependymal cells aligning with the lateral
ventricle. Moderate expression of nestin was detected in the
GFAPþ1 cells in this area (Fig. 8B, arrows), but intensely nestin-
labeled cells were not found to express GFAPþ1 (Fig. 8B, arrow-
head). Synemin was only rarely co-localized with GFAPþ1 (not
shown). Again, no differences were noted in this staining pattern at
the different stages of AD.
Hypertrophic astrocytes were intensely stained by vimentin and
GFAP, contained thicker cell processes, and appeared larger
compared to nonreactive astrocytes. GFAPþ1 cells that were sur-
rounded by reactive astrocytes clearly differed in morphology from
these cells (Fig. 8C and D, arrows). They were larger in diameter due
to considerably longer processes, and vimentin and GFAP expres-
sion was not apparent in these processes. Moreover, the
morphology of GFAPþ1 cells in areas of astrogliosis was not
noticeably different from GFAPþ1 cells in non-gliotic areas.
3.7. Number of GFAPþ1-expressing astrocytes is closely associated
with AD pathology
To investigate GFAPþ1 expression in relation to AD pathology, we
quantiﬁed the number of GFAPþ1 cells in relation to AD pathology in
the same sections. The total number of GFAPþ1 cells/cm2 ranged
from 4e82 and the number of GFAPþ1 cells/cm2 signiﬁcantly
correlated with the amyloid staging (spearman rank correlation:
RS ¼ 0.58, p < 0.001, Fig. 9A). Amyloid O was signiﬁcantly different
Fig. 3. GFAP isoform stainings in hippocampus (A) A dense network of astrocytic processes is present throughout the hippocampus; illustrated here in the CA4 region by GFAPmono
staining. In this area, the staining intensity and morphology of this network is hardly inﬂuenced by plaques. (B) GFAPc-term staining in stratum pyramidale of CA1 illustrating the
increased GFAP expression around some (arrowhead) but not all plaques (arrows). (C) GFAPc-term staining in stratum pyramidale of CA1 showing increased GFAP staining around
small fragmented Ab deposits (arrows). (D) Low magniﬁcation of the dentate region with the high density of GFAPd-positive astrocytes in the subgranular zone, hilus, and CA4. Note
the near absence of GFAPd-staining in the stratum moleculare. (E and E’) Double staining of GFAPd and GFAPc-term in the dentate gyrus. Processes extending into the granular cell
layer and the molecular layer are more GFAPc-term positive (arrowheads), whereas the cell bodies in the SGZ are more intensely stained for GFAPd (arrows), but the ratio differs
between cells (long arrow vs short arrow). (F and F’) High magniﬁcation of a typical GFAPd-positive cell in the hilus double stained with GFAPc-term. Proximal processes are double-
positive (arrows), whereas the ﬁner GFAPc-term processes are not detectable by GFAPd-staining (arrowheads). (A) NBB 97-003, male 82 years, Braak 5, amyloid B; (B and C) NBB 02-
050, female 95 years, Braak 4, amyloid B; (D and F) NBB 03-001, female 88 years, Braak 4, amyloid C; (E) NBB 05-027, female 64 years, Br 0, amyloid A. Abbreviations: SGZ,
subgranular zone; Str Gran, stratum granulosum; Str Mol, stratum moleculare.
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C (p < 0.001). The number of GFAPþ1 cells/cm2 also correlated with
tau Braak stages (RS ¼ 0.59, p < 0.001, Fig. 9B). Braak stage 0 was
signiﬁcantly different from Braak stages 2 through 6 (p  0.006).
GFAPþ1 cells were not clearly associated with plaques (Fig. 9C).
Only some GFAPþ1-expressing cells were found in close proximityto plaques, even with processes protruding through the plaques
(Fig. 9D).
Because the amyloid staging technique does not reﬂect the
precise level of amyloid deposition in the hippocampus, the total
number of amyloid plaques was quantiﬁed in the same sections
used for GFAPþ1 cell counts. With an automated segregation mask,
Fig. 4. GFAP isoform, vimentin, nestin, and synemin stainings near plaques in the hippocampus (A and A’) Triple staining for GFAPd, GFAPc-term, and Ab. In the hilus/CA4 region, the
intensity of the GFAPd staining is not much inﬂuenced by the presence of a plaque (asterisk). Compare the intensity of GFAPd-positive cells at some distance of a plaque (arrows)
with those nearby (arrowheads). Note the network of ﬁne processes positive for GFAPc-term. (B) In CA2 subregion, the same staining shows increased expression of GFAPd and
GFAPc-term in reactive astrocytes (arrow) associated with some plaques. (C) Triple staining for GFAPd, nestin, and vimentin in the CA4 region. Asterisks indicate the position of 2
plaques visible in the DAPI channel. Arrows indicate triple-positive astrocytes with labeled processes. Nestin staining with a granular pattern was found in the soma of GFAPd
astrocytes more distant from plaques (arrowheads). Blood vessels are immunopositive for nestin and vimentin but are GFAPd negative (short arrows). (D) Triple staining for GFAPd,
nestin, and vimentin in the CA2 region. Here, reactive astrocytes near plaques (*) are vimentin positive but nestin negative (arrows). Plaque core contains several vimentin-positive,
GFAPd/nestin-negative cells (red arrows). (E) Double staining for nestin and GFAPd in the subgranular zone of the dentate gyrus of a Braak 0 donor. A dense network of nestin- and
GFAPd-positive processes is seen. Inset highlights 2 nestin-positive cells, with 1 (left) being positive for GFAPd and the other (right) not. Arrow marks a nestin-positive blood vessel.
(F) Synemin and Ab double staining in CA2 subregion. Few synemin-positive cells are detected (arrows) but most did not have a clear spatial relation to plaques. (A) NBB 99-092,
male 92 years, Braak 2, amyloid C; (B) NBB 99-009, female 82 years, Braak 5, amyloid C; (C) NBB 07-015, female 73 years, Braak 6, amyloid C; (D) NBB 99-090, female 82 years, Braak
5, amyloid C; (E and F) NBB 05-027, female 64 years, Braak 0, amyloid A.
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Fig. 5. GFAPþ1 expression in a subpopulation of astrocytes. GFAPþ1 expression was often shown in astrocytes near the dentate gyrus (DG) of the hippocampus (A), in the sub-
ventricular zone of the lateral ventricle (LV) (B), and in subpial astrocytes (C), which have short processes toward the pia and long processes into deeper layers (arrowheads). GFAPþ1
expression was most common in relatively large astrocytes sometimes with multiple short processes (D) or with many long processes (E). Sometimes extraordinary GFAPþ1
expressing astrocytes were detected with striking thickenings in its processes (F, arrows). Frequently GFAPþ1 astrocyte processes (red) were found in contact with a blood vessel
(asterisk), labeled here by vimentin (green). The process terminating on a blood vessel often presented a clear endfeet structure, which is more clear at higher magniﬁcation (G,
boxed area). NBB 01-103, female 93 years, Braak 3, amyloid B (AeG).
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relative area of amyloid plaques (plaque coverage percentage) were
determined. Plaque number density was low in amyloid O (334 
167; mean  SEM) and amyloid A (413  219), and signiﬁcantly
increased at amyloid B (2326 421) and at amyloid C (3246 372).
Plaque number density positively correlated with GFAPa transcript
levels (RS ¼ 0.42, p ¼ 0.003). The plaque coverage followed the
same development.
The number of GFAPþ1 cells/cm2 showed a signiﬁcant positive
correlation with both plaque number density (RS ¼ 0.62, p <0.001; Fig. 9E) and with plaque coverage (Rs ¼ 0.47, p < 0.001).
The age of the Braak 0 and of the amyloid O-A donors was
slightly younger compared to the other groups, indicating that
age-dependent effects may also contribute to the observed in-
crease in the number of GFAPþ1 cells. When considering the
group of amyloid O-A donors with low plaque numbers, there
was indeed a signiﬁcant correlation with age estimated to add
0.23 GFAPþ1 cell/cm2 each year (RS ¼ 0.53, p ¼ 0.017) (Fig. 9F). In
addition, there was a signiﬁcant difference in the number of
GFAPþ1 cells/cm2 between males (22.0  0.2 GFAPþ1 cells/cm2;
Fig. 6. Double-labeling of GFAPþ1 with GFAPc-term antibody. (A) GFAPþ1 in most cases does not co-localize with GFAPc-term. Arrow indicates the soma of a GFAPþ1-positive cell
negative for GFAPc-term. Also the GFAPþ1 processes are not GFAPc-term positive (arrowheads). (B) Frequently found GFAPþ1 positive processes most likely originating from a cell
body (*) not positioned in the section also do not co-localize with GFAPc-term. Arrow points at a GFAPc-termepositive astrocyte. (C) Occasionally, a GFAPþ1-positive cell dou-
blestains with GFAPc-term at the soma (arrow) and proximal processes (arrowheads). (A and B) NBB 03-001, female 88 years, Braak 4, amyloid C; (C) NBB 01-017, male 79 years,
Braak 1, amyloid A.
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0.007). This difference is, to some extent, caused by the fact that
the average age of the female donors (82  2 years) was higher
compared to that of males (76  2 years, p < 0.007). Plaque
number density and plaque coverage was not different between
females and males. Statistical analysis of females and males still
revealed a highly signiﬁcant effect of Braak stage (females: Rs ¼
0.67, p < 0.001; males: RS ¼ 0.46, p < 0.005) and amyloid stage
(females RS ¼ 0.39, p ¼ 0.032; males Rs ¼ 0.46, p < 0.006). No
correlations were found between the number of GFAPþ1 cells/
cm2 and the ApoE genotype or post-mortem delay. In conclusion,
age, sex, and AD progression all have effects on the number of
GFAPþ1 cells/cm2 (Fig. 9F).3.8. GFAPþ1 expression in astrocytes is induced by Ab1-42 in vitro
In view of the increased number of GFAPþ1-expressing cells in
the course of AD, we testedwhether Ab could induce the expression
of this splice variant in U343 astrocytoma cells that normally do not
express GFAPþ1.We treated cells with 1 mmol/L of Ab1-42 oligomers
or ﬁbrils for 1 day (n ¼ 2), 3 days (n ¼ 4), or 7 days (n ¼ 3). First the
viability of U343 cells was measured with an MTT assay after
exposure to 1 mmol/L Ab1-42 oligomers and ﬁbrils at these time
points. Compared to untreated or DMSO treated cells, exposure to 1
mmol/L Ab oligomers for 1e7 days reduced formazan formation in
these cells by approximately 20%. Exposure to 1 mmol/L ﬁbrils
showed a considerably larger effect; 1 day of treatment already
Fig. 7. Double-labeling of GFAPþ1 with S100B and glutamine synthetase S100B (A and A’) and glutamine synthetase (B and B’) are expressed in many astrocytes (arrowheads) co-
localize with GFAPþ1-positive cells (arrow); however, also GFAPþ1 astrocytes (arrows) also are found that do not co-localize with glutamine synthetase (C and D) while being
surrounded with glutamine synthetaseeexpressing astrocytes (arrowheads), both in the hippocampus (C) and in the subventricular zone (D). (A and B) NBB 00-107, male 70 years,
Braak 5, amyloid C; (B) NBB 01-094, male 86 years, Braak 2, amyloid B.
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formationwas less than 50% compared to that in controls. However,
for both oligomers and ﬁbrils, the decrease was stabilized after 3
days (Fig. 10A). Microscopic inspection of the treated cell cultures
did not show obvious cell death or clear morphological changes
(not shown).
Immunostaining for GFAPþ1 expression in the Ab-treated cul-
tures revealed a small number of GFAPþ1-expressing cells after
treatment with 1 mmol/L Ab ﬁbrils for 1 day (Fig. 10B). More
frequent and larger clusters of GFAPþ1-expressing cells were
found after 3 days of Ab ﬁbril treatment in 2 of 4 experiments
(Fig. 10C). Also after 7 days of Ab ﬁbril treatment several GFAPþ1-expressing cells were detected in 1 experiment (Fig. 10D). After 1
day of Ab oligomer treatment, no GFAPþ1-positive cells were
observed; however, after 3 days exposure to Ab oligomers, several
GFAPþ1-expressing cells were found in 1 experiment (Fig. 10E),
and even more after 7 days of Ab oligomer treatment in all 3
experiments (Fig. 10F). In 1 experiment, a few GFAPþ1-expressing
cells were also found after 3 and 7 days in the control condition
without the presence of Ab in the culture (Fig. 10G). In addition to
GFAPþ1, we also stained for Ab, which showed some small green
spots in the oligomer-treated cultures (Fig. 10E, arrowheads) and
large aggregates in the ﬁbril-treated cultures (Fig. 10D,
arrowheads).
Fig. 8. Double-labeling of GFAPþ1 with intermediate ﬁlament proteins vimentin and nestin (A) In GFAPþ1-positive astrocytes Vimentin co-localizes with GFAPþ1 around the nucleus
(arrow) and in proximal processes. (B) Nestin is expressed in astrocytes in the subventricular zone. Low-intensity immunostaining for nestin can be detected in some GFAPþ1
astrocytes in this area (arrows), but cells with high-intensity staining for nestin (arrowhead) do not express GFAPþ1. In brains of older adults and of AD patients, many reactive
astrocytes express high levels of vimentin (C, arrowheads) and GFAPc-term (D, arrowheads). GFAPþ1-positive cells in these brains contain only low levels of vimentin and GFAPc-
term and have a distinct morphology (C and D, arrow). (A and B) NBB 01-096, female 68 years, Braak 1, amyloid A; (C) NBB 01-086, male 88 years, Braak 1, amyloid O; (D) NBB 01-141,
female 69 years, Braak 5, amyloid C.
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GFAPk or GFAPþ1 isoforms were overexpressed in SW-13cl.2
adrenal carcinoma cells by plasmid transfection (Supplementary
Fig. 1). Overexpression of GFAPd was reported previously, and
revealed that GFAPd alone is unable to form an IF network, and co-
expression with GFAPa results in a collapse of the existing network
(Roelofs et al., 2005). SW-13cl.2 cells lack endogenous expression of
cytoplasmic IF proteins, which enabled us to study whether GFAPþ1
proteins could homodimerize and form ﬁlaments by itself.Transfection of only GFAPa in SW-13cl.2 cells revealed a clear IF
network throughout the cell when stained for GFAPc-term
(Supplementary Fig. 1A), indicating self-assembly of GFAPa.
GFAPþ1 staining of cells transfected with GFAPD164
(Supplementary Fig. 1B), GFAPDEx6 (Supplementary Fig. 1C), or
GFAPk (Supplementary Fig. 1K) showed that these isoforms are not
capable of forming ﬁlaments by themselves. Co-transfections of
GFAPa and GFAPk or GFAPþ1 isoforms did not yield ﬁlaments when
cells were transfected with 25%e50% GFAPa (Supplementary
Fig. 1E, F, H, I, L, and M). Only in a number of cells that were
Fig. 9. Number of GFAPþ1-labeled cells signiﬁcantly correlates with AD pathology. Number of GFAPþ1 cells/cm2 signiﬁcantly increases with amyloid score (A) and Braak stage (B).
Asterisks show statistical signiﬁcant difference with amyloid O (* p < 0.05; *** p < 0.001) or with Braak 0 (* p < 0.05; ** p < 0.01,*** p < 0.001). (C and D) GFAPþ1-positive cells
(arrows) are found mostly at positions not clearly associated with amyloid plaques, but some are located in the proximity of amyloid deposits and make contact with plaques
without displaying the typical morphology of a reactive astrocyte (D). (E) Scatter plot with the values of all donors illustrating that the number of GFAPþ1 cells signiﬁcantly correlates
to the number of amyloid plaques/cm2 (RS ¼ 0.62; p < 0.001) but also illustrates the large variability in the number of GFAPþ1 cells at all AD stages. (F) Scatter plot of the number of
GFAPþ1 cells in relation to age of the donors. Trend line is based on the amyloid O and amyloid A donors with low plaque deposition revealing a signiﬁcant age-dependency (RS ¼
0.53; p ¼ 0.017). Note that the donors of amyloid B and C are above this trend line. Overall, female donors (data points labeled with a minus sign []) have a higher number of
GFAPþ1 cells/cm2 compared to males; when considering amyloid O and A donors this difference was not present, and in the amyloid B and C donors the difference showed a trend
(37.8  4.1 vs. 27.7  2.6; p < 0.07). (C and D) NBB 05-025, male, 84 years, Braak 3, amyloid C.
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Fig. 1G and J) or with 25% GFAPk (Supplementary Fig. 1M) small
ﬁlamentous structures were formed, but not as extensive as with
100% GFAPa (Supplementary Fig. 1A).
In addition, transfection of GFAP isoforms in U343 astrocytoma
cells that endogenously express GFAPa but not GFAPD164 or
GFAPDEx6, was performed to analyze possible heterodimer for-
mation and the effect of induced GFAPþ1 expression on the
morphology of these cells with a pre-existing IF network
(Supplementary Fig. 2). Transfection with GFAPþ1 isoforms
(Supplementary Fig. 2AeD) resulted in an improved ﬁlament for-
mation compared to SW-13cl.2 cells, but was still compromised
compared to untransfected U343 cells.
4. Discussion
The aim of this study was to characterize the expression pattern
of different GFAP isoforms in normal human hippocampal tissue
and in conditions with AD-related gliosis using an approachcomparable to that in our previous work in wild-type and AD mice
(Kamphuis et al., 2012). To this end, we have developed isoform
speciﬁc qPCR assays and used our unique collection of antibodies
against human GFAPd, GFAPþ1, and GFAPk. The main novel ﬁndings
are as follows: (1) The quantiﬁcation of relative expression levels of
the different GFAP isoform encoding transcripts in both control and
AD subjects shows that 7 different isoforms are expressed in all
samples; (2) novel isoforms GFAPDEx7 and GFAPz at the transcript
level in human brains were identiﬁed; (3) transcript levels of all
GFAP isoforms increase in concert with AD progression except for
GFAPD164 and GFAPDEx6; (4) GFAPd immunostainings show a
widespread distribution in human hippocampus, with a high
expression in the SGZ and CA4 region and an increased expression
in reactive astrocytes near plaques; (5) GFAPk antibodies do not
yield staining patterns; (6) immunostainings for frame-shifted
GFAPþ1 reveal a subpopulation of astrocytes with a characteristic
morphology not limited to AD cases; (7) the number of these
GFAPþ1 cells increases in the course of AD, whereas the cells could
not be typiﬁed as reactive astrocytes associated with plaques; and
Fig. 10. U343 astrocytoma cells treated with Ab1-42 oligomers and ﬁbrils (A) MTT assay results showing that formazan formation, reﬂecting cell viability, is decreased in U343 cells
treated with Ab1-42 oligomers and even more after treatment with Ab1-42 ﬁbrils (** p < 0.01; *** p < 0.001). After 1 day (B), 3 days (C), and 7 days (D) of exposure to Ab1-42 ﬁbrils,
several clusters of GFAPþ1-expressing cells were observed. Ab1-42 ﬁbrils (green) form large aggregates in vitro (D, arrowheads). After 3 days (E) and 7 days (F) of exposure to Ab1-42
oligomers, several GFAPþ1-expressing cells were observed, but also after 3 days of control treatment (G). Ab1-42 oligomers could sometimes be visualized by an Ab antibody as small
spots (green) in the cell culture (E, arrowheads). Inset in f shows the ﬁbrillary character of the GFAPþ1 staining.
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of GFAPþ1-positive cells.
4.1. GFAP isoform transcript levels in human hippocampus
In human hippocampal cDNA samples, GFAPa is the most abun-
dant isoform followed by GFAPd (1.4%), GFAPk (1.2%), GFAPz (0.2%),
GFAPD135 (0.2%), with other isoforms GFAPb, GFAPg, GFAPDEx6,GFAPD164, and GFAPDEx7 all at <0.01%. This proﬁle is based on
plasmid calibration curves, which does not correct for potential
different efﬁciencies in cDNA synthesis from the transcripts encod-
ing for the various isoforms. However, the mixture of oligodT and
random primers used, together with a slightly elevated incubation
temperature of 42 C, are the optimal conditions for an efﬁcient
conversion into cDNA. Based on our previouswork. (Kamphuis et al.,
2012), we now can conclude that the GFAP isoform expression
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GFAPa in human hippocampus is even more prevalent.
4.2. GFAP isoform transcript levels increase in human AD
In human cDNA samples fromAD donors all GFAP isoforms were
signiﬁcantly increased, reaching a 1.5- to 3.2-fold increase at end-
stage AD (amyloid C/Braak 6). The gradual increase of GFAPa
transcript levels paralleled the progression of AD reﬂected by the
number of plaques, amyloid scores, and Braak stages. In the APPs-
wePS1dE9 transgenicmousemodel, we described a similar increase
in transcript level of all detected GFAP isoforms (Kamphuis et al.,
2012). The GFAPþ1-encoding transcripts (GFAPD164, GFAPDEx6,
GFAPDEx7) showed a general trend to increase, which may be
coupled to the increased number of GFAPþ1 cells in AD. However,
the assessed levels of these isoforms are very low, quite variable,
and not detectable in all samples, and we do not know with cer-
tainty whether these transcripts originate only from GFAPþ1 cells
or whether they are expressed by all astrocytes at very low
abundance.
4.3. Astrocytes in AD hippocampus express several different GFAP
isoform
Fromour panel of GFAP antibodies, GFAPpan, GFAPmono, GFAPd,
and GFAPþ1 displayed immunostaining in sections. The staining of
GFAPþ1 in a subpopulation of astrocytes with a distinct morphology
is different from the mouse brain where we have been unable to
detect GFAPþ1 immunostaining in either wild-type or AD mice
(Kamphuis et al., 2012). The GFAPc-term antibody is speciﬁc for the
GFAPa C-terminal sequence, and we assume that the obtained
immunostaining pattern predominantly reﬂects the expression of
GFAPa in astrocytes and the increased GFAPa protein levels in
reactive astrocytes around some plaques.
Previously, we reported that, in the human brain, GFAPd is
differentially expressed in proliferating cells in the subventricular
zone (Condorelli et al., 1999a; Roelofs et al., 2005; van den Berge
et al., 2010). In the mouse brain, the distribution of GFAPd was
not restricted to the subventricular zone (Kamphuis et al., 2012). In
our experience, the optimal sensitivity for IF immunostaining is
obtained by using lightly ﬁxed cryosections of frozen tissue.
Following this method, we now demonstrate a clear GFAPd staining
in hippocampal astrocytes with a preferential localization in the
proximal processes. Astrocytes in the SVZ, SGZ, and CA4 region of
the hippocampus displayed strong immunostaining for GFAPd. The
overlap with nestin and GFAPd was only partial, and we conclude
that, in contrast to the SVZ (Roelofs et al., 2005; van den Berge et al.,
2010), GFAPd is not a speciﬁc stem cell marker in the SGZ. In line
with the increases in GFAPd transcript levels, GFAPd immuno-
staining was increased in reactive astrocytes around plaques.
GFAPk transcript was clearly detectable in all samples and levels
increased in AD tissue, but the predicted protein could not be
detected which is in line with our observations in mouse brain
model (Kamphuis et al., 2012).
Our observations are in good agreement with the outcome of
studies demonstrating that GFAP expression levels are highly
associated with plaque load (Hanzel et al., 1999; Muramori et al.,
1998; Vehmas et al., 2003). Exposure of astrocytes in culture to
different forms of Ab resulted in GFAP upregulation and various
other astroglial alterations such as the production of inhibitory
extracellular matrix proteins and a change of morphology without
compromising viability (Datki et al., 2004; Hu et al., 1998; Nielsen
et al., 2009; Salinero et al., 1997). Astrocytes are able to actively
remove Ab through uptake, which may reduce the amyloid depo-
sition in the brain (Allaman et al., 2010; Apelt et al., 2003; Nielsenet al., 2009; Pihlaja et al., 2008, 2011; Thal et al., 2000b;
Wisniewski and Wegiel, 1991; Wyss-Coray et al., 2003). As it has
become clear that the absence of GFAP alters the response of as-
trocytes in a profound manner, it may be hypothesized that the
increase in GFAP in reactive astrocytes inﬂuences plaque load. In
fact, in a recent study by Kraft et al., it was shown that GFAP/
vimentin/eAPPswePS1dE9 mice have an increased plaque load
and more dystrophic neurites around plaques, signifying a neuro-
protective function of the IF network in astrocytes (Kraft et al.,
2012; Otani et al., 2006). GFAP/ astrocytes fail to form a barrier-
like structure around Ab deposits (Xu et al., 1999) and have
impaired cell motility (Lepekhin et al., 2001). These observations
support an involvement of astrocytes and the IF network of astro-
cytes in the process of reactive gliosis as it occurs in AD.
The results of the transfection studies on SW-13cl.2 cells, lacking
endogenous expression of intermediate ﬁlament proteins, and on
U343 cells provided evidence that only GFAPa is able to form a
network of ﬁne ﬁlaments throughout the cell, whereas transfection
with GFAPd (Roelofs et al., 2005), GFAPk (Blechingberg et al., 2007),
and GFAPþ1 isoforms (the current paper) results in a compromised
network. The detrimental effects of GFAPd or GFAPþ1 on the
network could be partly counteracted by a co-transfection of GFAPa
or when cells with a pre-existing IF network were transfected.
Given the proﬁle of GFAP isoform transcript levels as determined in
human samples, it seems unlikely that, in vivo, the GFAP network is
compromised by high levels of GFAPd, as we did not observe GFAPd
staining aggregates in cells.
4.4. GFAPþ1 is expressed by morphologically distinct subpopulation
of astrocytes
In contrast to the mouse brain, we observed GFAPþ1-positive
cells in the human hippocampus, subiculum, entorhinal cortex,
caudate/putamen, spinal cord, and SVZ (Middeldorp et al., 2009b).
Recently, we have identiﬁed a low number of GFAPþ1 cells with a
shape comparable to those in the human brain, in the hippocampus
of a 15-year-old rhesus macaque, lending support to the existence
of this special type of cells. Most GFAPþ1 cells expressed the
astrocyte markers S100B and glutamine synthetase, indicating that
these cells are mature differentiated astrocytes, but not all have
these characteristics. Evidently, GFAPþ1 cells are a minority of the
total population of astrocytes. Their cellular shape clearly differs
from reactive astrocytes, plus vimentin and GFAPa expression in
these cells was not noticeably upregulated. Also, in other cases of
astrogliosis, for example as a result of an infarct, no GFAPþ1 cells
were found (unpublished observations). The most striking feature
of GFAPþ1 cells in vivo was the large size of these cells and the
presence of several remarkably long processes. Human protoplas-
mic astrocytes in the cortex range in domain diameter between 100
mm and 400 mm, with an average of 143 mm, and the longest pro-
cesses exhibit an average length of 98 mm (Oberheim et al., 2009).
Although some GFAPþ1-expressing cells ﬁt these measurements,
many GFAPþ1 cells had much longer processes, even up to 1 mm in
length. The morphology of the GFAPþ1-positive cells matches with
the morphology of varicose projection astrocytes in layers 5 and 6
of the human cortex (Oberheim et al., 2009). These cells were
shown to extend 1e5 long processes up to 1 mm in length termi-
nating in the neuropil or on the vasculature. Comparable to pro-
cesses of GFAPþ1 astrocytes, varicose projection astrocytes often
contacted brain capillaries. A noticeable difference is the lack of
regularly spaced varicosities present on the processes of GFAPþ1
cells (Oberheim et al., 2009). The interlaminar astrocytes shown by
Oberheim et al. resemble some of the subpial GFAPþ1 astrocytes
that we found in our study (Fig. 5C). Some of the morphological
differences between our study and the Oberheim study could be
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tissue sampling (post-mortem vs. surgical) and the detection
method (GFAPþ1 vs. GFAP antibodies).
The overexpression studies show that if, in these cells, a GFAPþ1
isoform becomes dominant over GFAPa, then this might account for
unusual IF network possibly underlying the unique shape of these
astrocytes. So far, despite several attempts, we have not been able to
determine which transcript underlies the GFAPþ1 protein levels in
the GFAPþ1-immunopositive cells in vivo. Isolation of GFAPþ1 cells
by laser dissection microscopy showed the presence of GFAPþ1
transcripts, but a consistent proﬁle did not emerge (not shown). It
must also be noted that our constructs express the N-terminus of
GFAPa; however, the exact sequence of the N-terminal head
domain of GFAPD164 and GFAPDEx6 transcripts in vivo has not yet
been determined. Therefore, these constructs may not represent
the endogenous expressed GFAPþ1 isoforms, and thus the IF for-
mation capacity might differ from the results we obtained with our
expression constructs.
4.5. Number of GFAPþ1 cells is increased in AD
Whereas it is unlikely that GFAPþ1 cells are reactive astrocytes,
we did ﬁnd that the number of these GFAPþ1-expressing astrocytes
signiﬁcantly increases during the progress of AD with lesser effects
of gender and age. The in vitro studies showed that treatment with
Ab1e42 oligomers and ﬁbrils increases the number of GFAPþ1-
positive cells, suggesting that elevated Ab level is a causative factor.
However, also in control culture, some GFAPþ1 inductionwas noted.
GFAPþ1-expressing cells in vitro always manifested as clusters,
which might indicate that, at least in vitro, not splicing but rather a
somatic mutation leading to a permanent transition of the frame-
shifted reading frame in 1 of the GFAP gene copies underlies the
GFAPþ1 in some cells. In 75%e85% of mouse cortical astrocytes, only
1 of the 2 GFAP loci in the genome is active, whereas the other is
rendered non-functional (Takizawa et al., 2008). A genetic modiﬁ-
cation changing the reading frame of the active locus into GFAPþ1
would also result in the complete loss of the GFAPa isoform, which
is in linewith the observation that themajority of GFAPþ1 cells does
not express detectable GFAPa. The gradual accumulation of such
mutations over the years could explain the slow rise in number
with age, and, in a previous study, we did not observe GFAPþ1 cells
in young adults (<50 years old) and during development (Boer
et al., 2010; Middeldorp et al., 2009b). Despite a high sponta-
neous DNA damage rate, irreversible DNAmutations occur only at a
very low frequency due to different repair systems. However, aging
may lead to an increased rate of DNA damage, whereas DNA dam-
age repair functions may become compromised and more error
prone (Li and Vijg, 2012). Using a mouse reporter model, an age-
related increase in mutation frequency in several tissues
including the brain was found. The brain showed a particularly low
mutation frequency, but in the hippocampus this signiﬁcantly
increased 2-fold between 7 months and 30 months of age (Busuttil
et al., 2007). Finally, several mechanisms regulate promoter activity
of the GFAP gene: DNA methylation, histone methylation and
acetylation, and spatial positioning (Bai et al., 2013; Kanski et al., in
press). A stable epigenetic alteration creating a dominance of a
usually rare isoform at the expense of GFAPamay also underlie the
existence of GFAPþ1 cells (Luco et al., 2011). Whether the increase in
number of GFAPþ1 cells in AD has any consequences for the disease
process cannot be derived from the data collected.
In conclusion, this study shows that at the transcript level the
canonical GFAPa isoform is accompanied by low levels of all other
known isoforms, and that, in AD, all transcript levels increase,
maintaining stable relative isoform RNA levels. Previously we
described GFAPd-isoform to be highly expressed in neurogenicastrocytes in the human subventricular zone (Roelofs et al., 2005;
van den Berge et al., 2010). However, we here conclude that
GFAPd is not an exclusive marker for these cells, because GFAPd-
stained astrocytes were found throughout the hippocampus as well
as in reactive astrocytes. GFAPþ1 is expressed in a subpopulation of
nonreactive astrocytes in elderly controls without dementia and in
subjects with AD. This relatively low number of GFAPþ1-expressing
cells cannot be categorized within 1 of the known astrocyte sub-
types. From the results presented in this study, we suggest that a
mutation underlies the formation of new GFAPþ1 cells out from
astrocytes, and that the frequency of this rare event is increased by
Ab-related cellular stress. Future exploration of underlying mech-
anisms concerning the function of GFAPþ1 proteins is needed to
elucidate the role of a specialized IF network in astrocytes in health
and disease.
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